Clinical Trials

2 trials
RecentStart dateEnrollment
Esthesioneuroblastoma, Olfactory × Cetuximab × CNS × Clear all
NCT00397384 2015-09-30

Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer

National Cancer Institute (NCI)

Phase 1 Completed
43 enrolled
CNSGastrointestinalHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Appendiceal Neoplasms, Bile Duct Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Tongue Neoplasms, Esthesioneuroblastoma, Olfactory, Gastrointestinal Stromal Tumors

NCT00101348 2014-06-11

Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
66 enrolled
CNSGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Esthesioneuroblastoma, Olfactory